Literature DB >> 3593812

Naltrexone and dysphoria: a double-blind placebo controlled trial.

R Malcolm, P M O'Neil, J M Von, P C Dickerson.   

Abstract

Naltrexone hydrochloride reportedly produces frequent dysphoria. This has led to speculation regarding the role of endorphins in the etiology of depression. Thirty-six subjects completed an 8-week trial of naltrexone or placebo with frequent mood assessments. No significant differences on POMS scales were noted for either subject group. One subject was discontinued from the study because of a severe dysphoric reaction. Naltrexone does not appear to significantly alter mood over a 2-month time course in nonaddicted, healthy individuals. Subpopulations of patients under physiological or psychological stress may react to naltrexone with dysphoric symptoms.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3593812     DOI: 10.1016/0006-3223(87)90202-2

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  10 in total

1.  Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone.

Authors:  Janice C Froehlich; Brett J Hausauer; Dennis D Rasmussen
Journal:  Alcohol Clin Exp Res       Date:  2013-07-22       Impact factor: 3.455

2.  Dynamic vaccine blocks relapse to compulsive intake of heroin.

Authors:  Joel E Schlosburg; Leandro F Vendruscolo; Paul T Bremer; Jonathan W Lockner; Carrie L Wade; Ashlee A K Nunes; G Neil Stowe; Scott Edwards; Kim D Janda; George F Koob
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

3.  Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice.

Authors:  Abdulrahman Almatroudi; Stephen M Husbands; Christopher P Bailey; Sarah J Bailey
Journal:  J Psychopharmacol       Date:  2015-06-04       Impact factor: 4.153

4.  Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism.

Authors:  Nolan R Williams; Boris D Heifets; Brandon S Bentzley; Christine Blasey; Keith D Sudheimer; Jessica Hawkins; David M Lyons; Alan F Schatzberg
Journal:  Mol Psychiatry       Date:  2019-08-29       Impact factor: 15.992

5.  Combining Varenicline (Chantix) with Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in a Rodent Model of Alcoholism.

Authors:  Janice C Froehlich; Stephen M Fischer; Julian E Dilley; Emily R Nicholson; Teal N Smith; Nick J Filosa; Logan C Rademacher
Journal:  Alcohol Clin Exp Res       Date:  2016-07-29       Impact factor: 3.455

6.  Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.

Authors:  Nolan R Williams; Boris D Heifets; Christine Blasey; Keith Sudheimer; Jaspreet Pannu; Heather Pankow; Jessica Hawkins; Justin Birnbaum; David M Lyons; Carolyn I Rodriguez; Alan F Schatzberg
Journal:  Am J Psychiatry       Date:  2018-08-29       Impact factor: 18.112

7.  A role for mu opioid receptors in cocaine-induced activity, sensitization, and reward in the rat.

Authors:  Joseph A Schroeder; Michele Hummel; Alpha D Simpson; Rizwan Sheikh; Avery R Soderman; Ellen M Unterwald
Journal:  Psychopharmacology (Berl)       Date:  2007-08-09       Impact factor: 4.530

8.  Behavioral architecture of opioid reward and aversion in C57BL/6 substrains.

Authors:  Stacey L Kirkpatrick; Camron D Bryant
Journal:  Front Behav Neurosci       Date:  2015-01-12       Impact factor: 3.558

Review 9.  Targeting opioid receptor signaling in depression: do we need selective κ opioid receptor antagonists?

Authors:  Sarah J Bailey; Stephen M Husbands
Journal:  Neuronal Signal       Date:  2018-05-14

10.  Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology.

Authors:  Jarred W Younger; Alex J Zautra; Eric T Cummins
Journal:  PLoS One       Date:  2009-04-13       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.